Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Financial terms for this agreement were not disclosed. These deals come amid a surge in ADC dealmaking across the pharmaceutical sector, as ADCs emerge as a key focus area in cancer research.

Corbus Pharmaceuticals (NASDAQ ... Padcev (enfortumab vedotin), another Nectin-4-directed ADC. In May, an RBC Capital Markets report cited CRB-701's longer half-life, more potent cell killing ...

He added, “We will strive to collaborate with LigaChem Biosciences to provide high-quality ADC pharmaceuticals to patients.” Yong-joo Kim, CEO of LigaChem Biosciences, noted, “We expect to ...